Patents by Inventor Rolf W. Pfirrmann

Rolf W. Pfirrmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210163432
    Abstract: Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed. These compounds were found to have significantly longer half-life compared to taurolidine and taurultam.
    Type: Application
    Filed: January 15, 2021
    Publication date: June 3, 2021
    Applicant: GEISTLICH PHARMA AG
    Inventors: Rolf W. PFIRRMANN, Hanns Moehler, Thomas Mueller
  • Patent number: 10968190
    Abstract: Methods for producing compounds useful in reactions to produce oxathiazin-like compounds are disclosed including a process of adding sodium 2-bromoethanesulfonate to a solution of benzyl alcohol and sodium benzyloxide to for mixture, boiling the mixture to reflux four times, concentrating under vacuum until dry, boiling with ethyl alcohol, filtering the ethyl alcohol, and concentrating to dryness to obtain solid sodium 2-benzyletherethanesulfonate.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: April 6, 2021
    Assignee: GEISTLICH PHARMA AG
    Inventor: Rolf W. Pfirrmann
  • Patent number: 10736902
    Abstract: A method of treating a patient suffering from TNBC by a multidisciplinary method involving treating the patient with a plurality of the following treatments: i) one or more checkpoint inhibitors; ii) hyperthermia treatment; iii) low dose chemotherapy; iv) Interleukin-2 (IL-2); and v) a compound selected from the group consisting of taurolidine, taurultam, oxathiazin-like compounds, and combinations thereof.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: August 11, 2020
    Assignee: GEISTLICH PHARMA AG
    Inventors: H. Paul Redmond, Rolf W. Pfirrmann
  • Patent number: 10544114
    Abstract: Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes for efficient and safe manufacture of compounds useful for making oxathiazin-like compounds useful for treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: January 28, 2020
    Assignee: GEISTLICH PHARMA AG
    Inventor: Rolf W. Pfirrmann
  • Publication number: 20190389819
    Abstract: Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed. These compounds were found to have significantly longer half-life compared to taurolidine and taurultam.
    Type: Application
    Filed: August 12, 2019
    Publication date: December 26, 2019
    Applicant: GEISTLICH PHARMA AG
    Inventor: Rolf W. PFIRRMANN
  • Patent number: 10392355
    Abstract: Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed. These compounds were found to have significantly longer half-life compared to taurolidine and taurultam.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: August 27, 2019
    Assignee: GEISTLICH PHARMA AG
    Inventor: Rolf W. Pfirrmann
  • Publication number: 20190091233
    Abstract: A method of treating a patient suffering from TNBC by a multidisciplinary method involving treating the patient with a plurality of the following treatments: i) one or more checkpoint inhibitors; ii) hyperthermia treatment; iii) low dose chemotherapy; iv) Interleukin-2 (IL-2); and v) a compound selected from the group consisting of taurolidine, taurultam, oxathiazin-like compounds, and combinations thereof.
    Type: Application
    Filed: March 17, 2017
    Publication date: March 28, 2019
    Applicant: GEISTLICH PHARMA AG
    Inventors: H. Paul REDMOND, Rolf W. PFIRRMANN
  • Publication number: 20190084950
    Abstract: Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes for efficient and safe manufacture of compounds useful for making oxathiazin-like compounds useful for treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed.
    Type: Application
    Filed: April 6, 2017
    Publication date: March 21, 2019
    Applicant: GEISTLICH PHARMA AG
    Inventor: Rolf W. PFIRRMANN
  • Publication number: 20180370932
    Abstract: Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed. These compounds were found to have significantly longer half-life compared to taurolidine and taurultam.
    Type: Application
    Filed: December 17, 2015
    Publication date: December 27, 2018
    Applicant: GEISTLICH PHARMA AG
    Inventor: Rolf W. PFIRRMANN
  • Patent number: 9844555
    Abstract: New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents. Compositions and methods of using oxathiazin-like compounds and their derivatives are disclosed.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: December 19, 2017
    Assignee: Geistlich Pharma AG
    Inventor: Rolf W. Pfirrmann
  • Publication number: 20170196876
    Abstract: New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents. Compositions and methods of using oxathiazin-like compounds and their derivatives are disclosed.
    Type: Application
    Filed: March 29, 2017
    Publication date: July 13, 2017
    Applicant: Geistlich Pharma AG
    Inventor: Rolf W. PFIRRMANN
  • Patent number: 9624187
    Abstract: New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents. Compositions and methods of using oxathiazin-like compounds and their derivatives are disclosed.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: April 18, 2017
    Assignee: Geistlich Pharma AG
    Inventor: Rolf W. Pfirrmann
  • Publication number: 20160159759
    Abstract: New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents. Compositions and methods of using oxathiazin-like compounds and their derivatives are disclosed.
    Type: Application
    Filed: December 3, 2015
    Publication date: June 9, 2016
    Applicant: Geistlich Pharma AG
    Inventor: Rolf W. PFIRRMANN
  • Patent number: 9241943
    Abstract: New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: January 26, 2016
    Assignee: Geistlich Pharma AG
    Inventor: Rolf W. Pfirrmann
  • Publication number: 20150182534
    Abstract: New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents.
    Type: Application
    Filed: June 17, 2013
    Publication date: July 2, 2015
    Applicant: GEISTLICH PHARMA AG
    Inventor: Rolf W. Pfirrmann
  • Patent number: 9028866
    Abstract: It now has been found that oral administration of pharmaceutical agents, including N-methylol transfer agents such as Taurolidine may be used to provide efficacious blood plasma concentration of the agents for treatment of diseases by providing release of the active agent into the duodenum or jejunum of a patient and/or at a pH of about 5.4 to about 6.5. Embodiments of the invention therefore provide oral dosage forms, compositions and methods for administration of pharmaceutical agents to the duodenum or jejunum of a patient, and/or which release at a pH of about 5.4 to about 6.5.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: May 12, 2015
    Assignee: Geistlich Pharma AG
    Inventors: Rolf W. Pfirrmann, Peter Geistlich
  • Patent number: 9012444
    Abstract: Tumor growth and metastases in cancer patients are inhibited by administration of a combination therapy including effective amounts of 5-Fluorouracil and a methylol transfer agent such as taurolidine, taurultam or mixtures thereof.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: April 21, 2015
    Assignee: Ed. Geistlich Soehne AG fuer Chemische Industrie
    Inventors: H. Paul Redmond, Rolf W. Pfirrmann
  • Patent number: 8852617
    Abstract: A dental care preparation in a form of a toothpaste or tooth gel dentifrice includes an antimicrobial amount of at least one antimicrobial N-methylol transfer agent, and at least one of a fluoride compound or a source of fluoride ions.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: October 7, 2014
    Assignee: Geistlich Pharma AG
    Inventors: Rolf W. Pfirrmann, Peter Geistlich
  • Publication number: 20130189199
    Abstract: A dental care preparation in a form of a toothpaste or tooth gel dentifrice includes an antimicrobial amount of at least one antimicrobial N-methylol transfer agent, and at least one of a fluoride compound or a source of fluoride ions.
    Type: Application
    Filed: September 26, 2011
    Publication date: July 25, 2013
    Applicant: GEISTLICH PHARMA AG
    Inventors: Rolf W. Pfirrmann, Peter Geistlich
  • Publication number: 20130089606
    Abstract: It now has been found that oral administration of pharmaceutical agents, including N-methylol transfer agents such as Taurolidine may be used to provide efficacious blood plasma concentration of the agents for treatment of diseases by providing release of the active agent into the duodenum or jejunum of a patient and/or at a pH of about 5.4 to about 6.5. Embodiments of the invention therefore provide oral dosage forms, compositions and methods for administration of pharmaceutical agents to the duodenum or jejunum of a patient, and/or which release at a pH of about 5.4 to about 6.5.
    Type: Application
    Filed: June 1, 2011
    Publication date: April 11, 2013
    Applicant: GEISTLICH PHARMA AG
    Inventors: Rolf W. Pfirrmann, Peter Geistlich